Device produces packaged batches of stem cells for regenerative medicine

May 27, 2014, Plataforma SINC, Spain
David Horna (right) in Aglaris Cell’s lab. Credit: PCM

The Spanish start-up Aglaris Cell is close to launching onto the market the world's first bioreactor that cultures cell in a fully automated way, without using toxic additives. The device has attracted interest from the University of Oxford and the pharmaceutical giant, Merk.

David Horna, a 33-year-old from Madrid and one of the co-founders of Aglaris Cell, whose offices are located in the Madrid Scientific Park (PCM), is in London this week to meet with investors to secure a second round of funding. Horna, alongside his two partners, Miquel Costa and Manuel A. González de la Peña, created the company a little over two years ago with the aim of developing a device that would automate stem cell cultures thereby making advances in the production of 'live' medicines.

The United Kingdom has fallen in love with the idea and last year the entrepreneurs secured a first investment of around one million euros from British business angels. They also caught the attention of ISIS, the University of Oxford's technology transfer office, which provides them with strategic and scientific advice.

As David Horna explained to SINC, after four years of intensive research and development, the prototype called Aglaris Facer 1.0, patented in 2012 in Spain and in the process of obtaining its international patent, "is practically ready to be sold on the market."

The idea of developing this device came about when the partners, who worked in various fields of biotechnology, noticed that more and more industries were using and tissues in their production processes.

Fully automatic

"We saw that the way live medicines from were being produced was highly manual, and so we came up with the idea of designing and developing a cell culture bioreactor that could automate the entire process. We believe that the stem cell-based therapies sector is going to expand rapidly in the years to come and will become a very promising business," Horna stated.

He noted that there are other bioreactors on the market and some have been able to automate some of the stages in the process, "but ours is the first in the world to perform all the process stages in a fully automated way."

Until now, an additive called trypsin was usually used in this type of culture, however, trypsin is toxic for cells and removes part of the membrane's proteins. "It has been used up to now because there was no other alternative, but our technology does not need to use this product," Horna said.

"Instead, our development uses an iterative method of cell culture which enables us to completely automate and remove the need for human involvement in the cell separation and washing stages, without using any additives that increase the toxicity level. We have achieved this by using smart surfaces that make cell adhesion and de-adhesion possible depending on changes in the environment," the co-founder explained.

He also adds that "we are currently finalising the developments that also make it possible to use the same device to produce genetically-modified cell lines for cellular reprogramming and gene therapies." These advances build on the work Horna undertook for his thesis on smart surfaces at the Spanish National Centre for Cardiovascular Research (CNIC) and the Sarrià Institute of Chemistry (IQS) which was published in the Advanced Healthcare Materials journal.

Afterwards, the patent for this technology was exclusively licenced to Aglaris Cell.

Stem cells in bags

"The process," he stated, "is as follows: before the culture, cells are taken from the patient, for instance fat cells obtained through liposuction, and then the stem cells are extracted. The next step is to inject the cells into the bioreactor where they will grow. The end product is cells packaged in a bag."

The device manages to produce a higher quantity of cells and of much higher quality than if they had been produced through manual culture, as there is no need to use trypsin. "We take much greater care of the cell and the culture quality; therefore the resulting 'live' medication can be far superior.. These cultures are used in regenerative medicine therapies and cell quality is extremely important."

The co-founder believes that this advance will be "extremely positive in cellular therapies as, apart from simplifying the process, it means the process can be repeated and carried out in a series. That means the batches can be the same throughout treatment, making the treatment better and lowering the risk of contamination."

David Horna explained that cell cultures are usually grown in laminar flow hoods and that, although these are highly-controlled environments, there is always a risk of contamination; the risk that some agent, like a dust particle for instance, could get in. "On the other hand, Aglaris Facer 1.0 is fully sealed and isolated from the external environment," he underlined.

The company is currently putting the final touches to the prototype "to make it look nice" before entering the commercial stage. In addition to British institutional and investment support, Aglaris Cell has been receiving strategic advice from the Merk which has taken an interest in the product, Horna stated.

Disposable consumables

The device has two parts: what those in the firm call the 'smart' part which contains all the engineering components, the computer, valves, pumps and sensors; and the 'dumb' part, which contains the consumables. It is in this second part, which is like a disposable cartridge, that the culture is grown. "It's important that this part is disposable because you must avoid cross contamination when working with 'live' medication," the entrepreneur said.

"This gives us a massive advantage because, by changing this consumable, this means the device can have numerous different functions. Apart from the culture cartridge, we have another cartridge almost ready in which you will be able to modify, differentiate or reprogramme cells. You will be able to play with biology a little bit."

According to the co-founder, potential customers of this system could be companies that develop therapies based on stem . In Spain, for example, there is a company called Histocell, a University of the Basque Country spin-off that produces cultures to regenerate bones, heal wounds and inflammatory diseases. Another is Cellerix, which has merged with the Belgian company TiGenix, and grows cultures to repair knee cartilage and anal fistula and has products at an advanced clinical stage, very close to marketing. You could also add any user of cells, "as the Aglaris Facer 1.0 is a stand-alone cell culture device," Horna emphasised.

The company is currently in talks with a Madrid hospital, whose name it cannot reveal just yet, to conduct a joint study and publish it in a scientific journal.

Explore further: A protein required for integrity of induced pluripotent stem cells

Related Stories

A protein required for integrity of induced pluripotent stem cells

April 21, 2014
Cell reprogramming converts specialised cells such as nerve cells or skin cells towards an embryonic stem cell state. This reversal in the evolutionary development of cells also requires a reversal in the biology of telomeres, ...

Researchers discover unique suspension technique for large-scale stem cell production

April 5, 2012
Post-doctoral researcher David Fluri and Professor Peter Zandstra at the University of Toronto's Institute of Biomaterials and Biomedical Engineering (IBBME) have developed a unique new technique for growing stem cells that ...

Human stem cell-derived hepatocytes regenerate liver function

July 27, 2013
Researchers have generated functional hepatocytes from human stem cells, transplanted them into mice with acute liver injury, and shown the ability of these stem-cell derived human liver cells to function normally and increase ...

Major breakthrough in stem cell manufacturing technology

March 31, 2014
Scientists at The University of Nottingham have developed a new substance which could simplify the manufacture of cell therapy in the pioneering world of regenerative medicine.

Screening for transformed human mesenchymal stromal cells with tumorigenic potential

January 29, 2014
Researchers at Erasmus University Medical Center Rotterdam, The Netherlands, led by Dr. Qiuwei Pan and Dr. Luc van der Laan, have discovered that spontaneous tumorigenic transformation of human mesenchymal stem/stromal cells ...

Extremely small-scale incubator microscope to examine cells in time lapse

May 26, 2014
Biologists and doctors rely heavily on incubators and microscopes. Now the Fraunhofer Institute for Biomedical Engineering IBMT has come up with a novel solution that combines the functions of both these tools in a compact ...

Recommended for you

Discovery of inner ear function may improve diagnosis of hearing impairment

October 15, 2018
Results from a research study published in Nature Communications show how the inner ear processes speech, something that has until now been unknown. The authors of the report include researchers from Linköping University, ...

Team's study reveals hidden lives of medical biomarkers

October 12, 2018
What do medical biomarkers do on evenings and weekends, when they might be considered off the clock?

Widespread errors in 'proofreading' cause inherited blindness

October 12, 2018
Mistakes in "proofreading" the genetic code of retinal cells is the cause of a form of inherited blindness, retinitis pigmentosa (RP) caused by mutations in splicing factors.

Researchers create a functional salivary gland organoid

October 11, 2018
A research group led by scientists from Showa University and the RIKEN Center for Biosystems Dynamics Research in Japan have, for the first time, succeeded in growing three-dimensional salivary gland tissue that, when implanted ...

Lassa fever vaccine shows promise and reveals new test for immunity

October 11, 2018
Lassa fever belongs to the same class of hemorrhagic fevers as Ebola. Like Ebola, it has been a major health threat in Western Africa, infecting 100,000-300,000 people and killing 5,000 per year. A new vaccine against both ...

Genetically engineered 3-D human muscle transplant in a murine model

October 10, 2018
A growing need for tissues and organs in surgical reconstruction is addressed by the promising field of tissue engineering. For instance, muscle atrophy results from severe traumatic events including deep burns and cancer, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.